These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

174 related items for PubMed ID: 8580835

  • 1. Favorable pharmacodynamic features and superior anti-leukemic activity of B43 (anti-CD19) immunotoxins containing two pokeweed antiviral protein molecules covalently linked to each monoclonal antibody molecule.
    Myers DE, Yanishevski Y, Masson E, Irvin JD, Evans WE, Uckun FM.
    Leuk Lymphoma; 1995 Jun; 18(1-2):93-102. PubMed ID: 8580835
    [Abstract] [Full Text] [Related]

  • 2. Effects of the intermolecular toxin-monoclonal antibody linkage on the in vivo stability, immunogenicity and anti-leukemic activity of B43 (anti-CD19) pokeweed antiviral protein immunotoxin.
    Uckun FM, Myers DE, Irvin JD, Kuebelbeck VM, Finnegan D, Chelstrom LM, Houston LL.
    Leuk Lymphoma; 1993 Apr; 9(6):459-76. PubMed ID: 7687916
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. In vivo efficacy of B43 (anti-CD19)-pokeweed antiviral protein immunotoxin against human pre-B cell acute lymphoblastic leukemia in mice with severe combined immunodeficiency.
    Uckun FM, Manivel C, Arthur D, Chelstrom LM, Finnegan D, Tuel-Ahlgren L, Irvin JD, Myers DE, Gunther R.
    Blood; 1992 May 01; 79(9):2201-14. PubMed ID: 1373967
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. In vitro and in vivo antileukemic activity of B43-pokeweed antiviral protein against radiation-resistant human B-cell precursor leukemia cells.
    Waddick KG, Myers DE, Gunther R, Chelstrom LM, Chandan-Langlie M, Irvin JD, Tumer N, Uckun FM.
    Blood; 1995 Dec 01; 86(11):4228-33. PubMed ID: 7492781
    [Abstract] [Full Text] [Related]

  • 9. Effective immunochemotherapy of CALLA+C mu+ human pre-B acute lymphoblastic leukemia in mice with severe combined immunodeficiency using B43 (anti-CD19) pokeweed antiviral protein immunotoxin plus cyclophosphamide.
    Uckun FM, Chelstrom LM, Finnegan D, Tuel-Ahlgren L, Manivel C, Irvin JD, Myers DE, Gunther R.
    Blood; 1992 Jun 15; 79(12):3116-29. PubMed ID: 1375841
    [Abstract] [Full Text] [Related]

  • 10. Toxicity profile of the investigational new biotherapeutic agent, B43 (anti-CD19)-pokeweed antiviral protein immunotoxin.
    Gunther R, Chelstrom LM, Wendorf HR, Schneider EA, Covalciuc K, Johnson B, Clementson D, Irvin JD, Myers DE, Uckun FM.
    Leuk Lymphoma; 1996 Jun 15; 22(1-2):61-70, follow.186, color plate II-V. PubMed ID: 8724529
    [Abstract] [Full Text] [Related]

  • 11. An anti-CD72 immunotoxin against therapy-refractory B-lineage acute lymphoblastic leukemia.
    Myers DE, Uckun FM.
    Leuk Lymphoma; 1995 Jun 15; 18(1-2):119-22. PubMed ID: 8580813
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Combined therapeutic efficacy of the thymidylate synthase inhibitor ZD1694 (Tomudex) and the immunotoxin B43(anti-CD19)-PAP in a SCID mouse model of human B-lineage acute lymphoblastic leukemia.
    Ek O, Reaman GH, Crankshaw DL, Chelstrom LM, Myers DE, Uckun FM.
    Leuk Lymphoma; 1998 Feb 15; 28(5-6):509-14. PubMed ID: 9613980
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Biotherapy for xenografted human central nervous system leukemia in mice with severe combined immunodeficiency using B43 (anti-CD19)-pokeweed antiviral protein immunotoxin.
    Gunther R, Chelstrom LM, Tuel-Ahlgren L, Simon J, Myers DE, Uckun FM.
    Blood; 1995 May 01; 85(9):2537-45. PubMed ID: 7537120
    [Abstract] [Full Text] [Related]

  • 18. Feasibility Study of a Novel Experimental Induction Protocol Combining B43-PAP (Anti-CD19) Immunotoxin With Standard Induction Chemotherapy in Children and Adolescents With Relapsed B-Lineage ALL: A Report From the Children's Oncology Group.
    Meany HJ, Seibel NL, Krailo M, Villaluna D, Chen Z, Gaynon P, Neglia JP, Park JR, Hutchinson R, Sato JK, Wells RJ, Woods WG, Reaman G.
    J Immunother; 2015 Sep 01; 38(7):299-305. PubMed ID: 26261894
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Anti-CD30 (BER=H2) immunotoxins containing the type-1 ribosome-inactivating proteins momordin and PAP-S (pokeweed antiviral protein from seeds) display powerful antitumour activity against CD30+ tumour cells in vitro and in SCID mice.
    Terenzi A, Bolognesi A, Pasqualucci L, Flenghi L, Pileri S, Stein H, Kadin M, Bigerna B, Polito L, Tazzari PL, Martelli MF, Stirpe F, Falini B.
    Br J Haematol; 1996 Mar 01; 92(4):872-9. PubMed ID: 8616080
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.